Renaissance Technologies
JANX icon

Renaissance Technologies’s Janux Therapeutics JANX Stock Holding History

Renaissance Technologies’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-92,899
Closed -$3.5M – 3745
2024
Q1 		$3.5M Buy
+92,899
New +$2.02M 0.01% 1650
2023
Q4 		– Sell
-26,100
Closed -$263K – 3923
2023
Q3 		$263K Buy
26,100
+11,300
+76% +$130K ﹤0.01% 2994
2023
Q2 		$176K Buy
+14,800
New +$198K ﹤0.01% 3331

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies's JANX Position: Q2 2024 in Review

Renaissance Technologies sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 92,899 shares — an estimated $3.5M sold.

Renaissance Technologies first reported a position in JANX in Q2 2023 and held it in 3 quarters. The position peaked at $3.5M in Q1 2024. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

  • Renaissance Technologies reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 92,899 Janux Therapeutics shares in Q2 2024, an estimated $3.5M.
  • Renaissance Technologies first reported a position in Janux Therapeutics in Q2 2023 and held it in 3 quarters.
  • Renaissance Technologies's Janux Therapeutics position peaked at $3.5M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.